McDermott Advises Groupe Bruxelles Lambert on Strategic Investment in Rayner

Key Takeaways

• GBL invests €0.5 bn for 45% stake in Rayner.
• Rayner supplies intraocular lenses in over 80 countries.
• Deal enhances GBL’s private‑asset exposure in healthcare sector.
• Co‑control arrangement includes CVC and Rayner management.
• McDermond led cross‑border advisory team for transaction.

Summary

McDermott Will & Schulte advised Groupe Bruxelles Lambert (GBL) on a strategic investment that will give GBL a 45% co‑control stake in Rayner, a leading UK‑based ophthalmic MedTech specialist. GBL will contribute €0.5 billion of equity alongside existing shareholders CVC and Rayner’s management team. Rayner manufactures intraocular lenses and sells products in more than 80 countries across six continents. The deal aligns with GBL’s mid‑term plan to broaden its private‑asset exposure, particularly in high‑growth healthcare sectors.

Pulse Analysis

Private‑equity firms are increasingly targeting medtech companies that combine stable cash flows with strong growth trajectories. Groupe Bruxelles Lambert’s €0.5 billion injection into Rayner reflects that strategic calculus, adding a sizable minority position while retaining co‑control rights. GBL, with a €14 billion net asset value, is leveraging its long‑term investment mandate to diversify beyond traditional listed holdings, betting on the resilience of ophthalmic devices amid an aging global population and rising demand for vision‑correction procedures.

Rayner, headquartered in the United Kingdom, has built a reputation for high‑quality intraocular lenses and related ophthalmic products, distributing to more than 80 countries. The capital infusion will likely fund R&D pipelines, expand manufacturing capacity, and support market‑entry initiatives in emerging regions where cataract surgery volumes are climbing. By partnering with existing shareholders CVC and the management team, GBL secures operational insight and aligns incentives, positioning Rayner to capture a larger share of the projected $15 billion global intraocular lens market over the next decade.

The deal also highlights the role of specialist legal advisers in cross‑border, multidisciplinary transactions. McDermott’s health‑focused team orchestrated the agreement, navigating regulatory, tax, and governance complexities inherent in a co‑control structure. As more institutional investors seek exposure to healthcare innovation, similar collaborations between private‑equity houses and seasoned counsel are expected to rise, shaping the competitive landscape of medtech financing and accelerating product pipelines worldwide.